Latest News & Updates
The growing use of genetic biomarker tests to screen, monitor, diagnose, and treat patients with cancer has the potential to improve outcomes and reduce costs, but payment systems for covering and reimbursing for these tests have fallen behind the times.
Dr. Maurie Markman discusses how the transition to the new therapeutic paradigm of oral therapies necessitates that we consider unique aspects of this strategy that may negatively impact outcomes compared with an approach of systemic antineoplastic drug administration.
Dr. Andre Goy discusses efforts to improve "compassionate use" programs that expand access to promising drugs that are not yet approved by the FDA.
The lack of comprehensive rehabilitation services is a profound source of unnecessary suffering for survivors.
ASCO has proposed a series of payment reforms that it says would significantly increase physician pay and the breadth of patient services available while lowering the overall cost of cancer care.
Latest Peer Exchange Discussions
Evan Y. Yu, MD, and Dean F. Bajorin, MD, discuss second- and third-line treatments of muscle-invasive bladder cancer. View Now
Matthew H. Taylor, MD, describes the challenge of selecting which FDA-approved agent to start first. View Now
In this segment, Marwan Fakih, MD discusses the promise of TAS-102 for refractory metastatic colorectal cancer. View Now
Most Popular Right Now
Online CME Activities